<DOC>
	<DOCNO>NCT02257684</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness , safety , dosage pegcrisantaspase patient Acute Lymphoblastic Leukemia ( ALL ) / Lymphoblastic Lymphoma ( LBL ) .</brief_summary>
	<brief_title>A Dose Confirmation Pharmacokinetic Study Pegcrisantaspase Administered Intravenous ( IV ) Infusion Children Young Adults With Acute Lymphoblastic Leukemia ( ALL ) /Lymphoblastic Lymphoma ( LBL ) . Following Hypersensitivity Pegaspargase ( Oncaspar )</brief_title>
	<detailed_description>The purpose study assess response rate child young adult ALL/LBL hypersensitivity pegaspargase define proportion subject serum asparaginase activity ( SAA ) level ≥ 0.1 IU/mL 14 day follow first IV pegcrisantaspase dose Course 1 . Also , assess safety IV pegcrisantaspase therapy child young adult ALL/LBL hypersensitivity pegaspargase .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<criteria>1 . Have diagnosis ALL/LBL 2 . Be &gt; 1 ≤ 21 year age study enrollment 3 . Have ≥ Grade 2 allergic reaction ( Common Terminology Criteria Adverse Events [ CTCAE ] v4.03 ) pegaspargase 4 . Have ≥ 1 dose ( ) pegaspargase remain his/her treatment plan 5 . Have document SAA level limit quantitation per analytical method . 6 . Subjects must , opinion investigator , fully recover prior allergic reaction pegaspargase . Subjects must complete antihistamine , epinephrine , and/or corticosteroid treatment allergic reaction ≥ 24 hour prior pegcrisantaspase administration . 7 . Subjects must performance status corresponding : Karnofsky ≥ 50 ( subject &gt; 16 year age ) Lansky ≥ 50 ( subject ≤ 16 year age ) 8 . Adequate Renal Function Defined : Creatinine clearance radioisotope GFR ≥ 70 mL/min/1.73 m2 A serum creatinine base age/gender follow : Age Maximum Serum Creatinine ( mg/dL ) Male Female 1 &lt; 2 year 0.6 0.6 2 &lt; 6 year 0.8 0.8 6 &lt; 10 year 1 1 10 &lt; 13 year 1.2 1.2 13 &lt; 16 year 1.5 1.4 ≥ 16 year 1.7 1.4 The threshold creatinine value table derive Schwartz formula estimate GFR ( Schwartz &amp; Gauthier 1985 ) utilize child length stature data publish CDC . 9 . Adequate Liver Function define : Bilirubin level ≤ 2.5x ULN age , Direct ( conjugate ) Bilirubin &lt; 0.5 mg/dLSGPT ( ALT ) ≤ 225 U/L . For purpose study , ULN SGPT 45 U/L . 10 . Subjects sexually active must agree use medically acceptable method contraception throughout entire study period 4 week study complete . Medically acceptable method contraception may use subject and/or partner include abstinence , birth control pills patch , diaphragm spermicide , condom vaginal spermicide , surgical sterilization , postmenopausal , vasectomy ( &gt; 6 month prior baseline ) , progestin implant injection . 11 . Able understand sign write informed consent . All subject and/or parent legally authorize representative must sign write informed consent . Assent , appropriate , obtain accord institutional guideline . 1 . Have previously receive Erwinia asparaginase 2 . Are receive another investigational agent receive investigational agent subsequent phase protocol therapy include asparaginase 3 . Have history ≥ Grade 3 pancreatitis ( CTCAE v4.03 ) 4 . Prior history CNS thrombotic event ≥ Grade 3 ( CTCAE v4.03 ) thrombotic event , exclude catheterassociated clot 5 . Prior history asparaginaseassociated ≥ Grade 3 ( CTCAE v4.03 ) hemorrhagic event asparaginaseassociated thrombus require anticoagulation therapy 6 . Blood triglyceride level &gt; 500 mg/dL &gt; 5.6 mmol/L 7 . Hyperglycemia require insulin therapy 8 . QTc prolongation ≥ 550 msec 9 . Subjects opinion investigator may able comply safety monitoring requirement study 10 . Subjects serious active disease comorbid medical condition ( accord investigator 's decision ) , psychiatric illness would prevent subject signing informed consent form , assent form inform consent form parent , pending institutional requirement , per investigator 's opinion , would prevent subject complete one course pegcrisantaspase . Pregnant lactating female females childbearing potential willing use adequate method birth control duration study . Female subject lactate agree stop breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ALL</keyword>
	<keyword>LBL</keyword>
</DOC>